Status: Recruiting
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the incidence of adverse events (AEs), adverse drug reactions (ADRs), adverse events of special interest (AESIs), and serious ADRs at 12, 26, and 52 weeks after treatment.
Participants needed: 30
Trial details
Phase: Phase 4Age: 6-17Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Updated: Sep 10, 2026Locations: 1
Eligibility criteria
Age is between 6 years old (inclusive) and 17 years old (inclusive), regardless... [+2]
(1) According to the instruction manual of Adalimumab Solution for Injection and... [+2]